Eloxx Pharmaceuticals, Inc.
ELOX
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 51.04% | 44.82% | 55.96% | 45.95% | 31.15% |
| Total Depreciation and Amortization | 2.50% | -8.78% | -32.38% | -27.60% | -20.46% |
| Total Amortization of Deferred Charges | -30.44% | -4.26% | 23.73% | 28.81% | 22.70% |
| Total Other Non-Cash Items | -41.65% | -43.32% | -90.64% | -90.12% | -86.81% |
| Change in Net Operating Assets | -357.62% | -210.93% | -2,026.28% | 88.60% | 128.39% |
| Cash from Operations | 50.18% | 41.54% | 20.75% | 9.02% | -21.44% |
| Capital Expenditure | 100.00% | 55.14% | 45.00% | 25.84% | -24.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 400.00% | 78.50% | -102.15% | -103.21% | -104.14% |
| Total Debt Issued | -- | -- | -- | -- | -100.30% |
| Total Debt Repaid | -- | 15.57% | 25.98% | -- | 100.00% |
| Issuance of Common Stock | -- | 8,300.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | 48.55% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -91.26% | -75.22% | -75.22% | 201.99% | 191.30% |
| Cash from Financing | -125.06% | -141.79% | -110.06% | -82.65% | -83.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.85% | 3.37% | -260.36% | -229.46% | -226.45% |